Immunotherapy May Benefit Stage 4 Melanoma Despite Signs of Progression

The outlook for malignant melanoma, a skin cancer once among the most difficult cancers to treat, changed dramatically in 2012 with the introduction of a new generation of immunotherapy drugs. Rather than directly killing cancer cells, these treatments activate the immune system against cancer. Beginning with melanoma, immunotherapies have since received FDA approval for numerous cancers.
Our current treatment approach in stage 4 (metastatic) melanoma is to use immunotherapies sequentially and, if the patient’s tumor is positive for a BRAF mutation , drugs targeting that mutation. Treatment continues while the patient responds, meaning the tumor shrinks or stops growing. Once the response ends, another treatment is introduced.
As a general principle in oncology, when a treatment stops working, cancer cells are considered to have developed resistance to that agent. Therefore, even when available options are exhausted, a previously used drug is generally not chosen again. Immunotherapies differ from conventional chemotherapy, however, because they act through immune cells rather than directly on cancer cells. This raises the question: could we approach tumor resistance to immunotherapy differently? This question has therefore come to the fore.
With this idea in mind, researchers published a study in JAMA Oncologyin which 85 of 526 patients with stage 4 melanoma continued receiving the immunotherapy drug nivolumab (brand name Opdivo) despite disease progression, meaning worsening. Of those 85 patients treated despite signs of progression, 24 (28%) had tumor shrinkage of more than 30%, a meaningful response. At the time of analysis, 87% of patients responding despite earlier signs of progression were still alive.
At 24 months, overall survival was 59% in the group treated despite signs of progression, compared with 25% among the other patients. No significant difference in treatment adverse effects was found.
In conclusion, some patients with stage 4 malignant melanoma benefit from continuing immunotherapy despite earlier signs of cancer progression during treatment. This study suggests that we should reconsider how we assess immunotherapy responses and that, when a patient’s condition has not substantially deteriorated, treatment should not be changed solely on the basis of imaging findings.
Sources
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression.
JAMA Oncol. June 29, 2017
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.